16 news items
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
AGX
AMSWA
AONC
7 Jun 24
18.7% to $0.6916. Canaccord Genuity analyst John Newman maintained Seres Therapeutics with a Buy and lowered the price target from $15 to $10
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy
MAIA
7 Jun 24
role of telomere targeting as a viable therapeutic strategy for cancer treatment
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
MAIA
7 Jun 24
company focused on developing telomere-targeting immunotherapies for cancer treatment, has unveiled
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
BMRN
EXEL
GMAB
7 Jun 24
. (NYSE:MAIA), a trailblazer in clinical-stage biopharmaceuticals focusing on targeted immunotherapies
MAIA Biotechnology Announces Year-to-Date Highlights And Achievements, Including Clinical Progress Of Lead Candidate THIO, A First-In-Class Cancer Telomere Targeting Agent For Non-Small Cell Lung Cancer (NSCLC)
MAIA
6 Jun 24
kywyal32v2zufx1011murby9fbi 2sqf685ktbx707zv94l35k9fe1yaa6yv
MAIA
6 Jun 24
biopharmaceutical company developing targeted immunotherapies for cancer, today announced Company highlights and key achievements year-to-date, including
h3hwrw1y2pbycj
CORT
HALO
MAIA
6 Jun 24
market is driven by advancements in targeted
hhugmpsbs4kain2ew9cvmajrsgc0vfgsxzhsw25xcvpdvn 1pf7gtkhcu5
MAIA
4 Jun 24
biopharmaceutical company developing targeted immunotherapies for cancer, today announced new efficacy data from its Phase 2 THIO-101 clinical trial
5c04pnsx0fl c9oa5lesitqi54e7lq713mojpt52vpby0cwwxe
AFMD
ALBT
BPTH
4 Jun 24
of traders and investors with its innovative approaches to cancer treatment, focusing on telomere-targeting therapies. The company is scheduled to present
n5u1k3wimqtuputcbbm8gynj44880nf7qmw6y82syfty5
CBAT
MAIA
NTRB
4 Jun 24
expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email
s6jvk16jantn9spmcn4bkr62kiip8e3up0f 1r8lt2ecca8rru8p79wxajz
CRL
IQV
MAIA
31 May 24
Therapy
MAIA Biotechnology’s leading product candidate, THIO, is a first-in-class telomere-targeting agent
a4ij5hm92obbd
MAIA
22 May 24
treatments that target cancer's replication mechanism in a more efficacious and less harmful manner than traditional therapies.Company Background
uqz81x8hdc7orxuyl95xgrsftne8hp2louyybj2x9udfs6
MAIA
17 May 24
), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced its participation in the upcoming BIO International
sg13xt7zajxm88wk4h1uilkn qdbzxpo
MAIA
16 May 24
-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract about its Phase 2 THIO-101 clinical
exjxm7uuihyrywwwb4ca
MAIA
30 Apr 24
., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted
j1of6zzh0fx5l2jyg6kx0fxwt3bjm aqs15sq8hwt60t0ru
MAIA
5 Apr 24
) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman
- Prev
- 1
- Next